StockMacro
Company, fund or insider

Help

Menu

Azora Therapeutics

$3.85 -21% in 6 monthsMarket cap $55.0M

AZR on XNAS, Health Care, Azora Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Net loss of $120.6M over 12 months against $22M of cash, with three officer changes in 90 days.

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.

Industry
Pharmaceutical preparations (Health Care)
Employees
6
Website
azoratherapeutics.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 5 Mar 2027 (an estimate: a year ago it reported on 6 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $64.6M.
Quarter to 31 Dec 2021: revenue –, net income -$5.8MQuarter to 31 Mar 2022: revenue –, net income -$2.9MQuarter to 30 Jun 2022: revenue –, net income -$3.8MQuarter to 30 Sep 2022: revenue –, net income -$3.1MQuarter to 31 Dec 2022: revenue –, net income -$2.9MQuarter to 31 Mar 2023: revenue –, net income -$2.9MQuarter to 30 Jun 2023: revenue –, net income $1.1MQuarter to 30 Sep 2023: revenue –, net income -$1.4MQuarter to 31 Dec 2023: revenue –, net income -$1.9MQuarter to 31 Mar 2024: revenue –, net income -$6.5MQuarter to 30 Jun 2024: revenue –, net income -$2.5MQuarter to 30 Sep 2024: revenue –, net income -$2.2MQuarter to 31 Dec 2024: revenue –, net income -$2.1MQuarter to 31 Mar 2025: revenue –, net income -$2.2MQuarter to 30 Jun 2025: revenue –, net income -$2.0MQuarter to 30 Sep 2025: revenue –, net income -$1.8MQuarter to 31 Dec 2025: revenue –, net income -$2.0MQuarter to 31 Mar 2026: revenue –, net income -$2.0MQuarter to 30 Jun 2026: revenue –, net income -$52.0MQuarter to 30 Sep 2026: revenue –, net income -$64.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $64.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$64.6M
30 Jun 2026–-$52.0M
31 Mar 2026–-$2.0M
31 Dec 2025–-$2.0M
30 Sep 2025–-$1.8M
30 Jun 2025–-$2.0M
31 Mar 2025–-$2.2M
31 Dec 2024–-$2.1M
30 Sep 2024–-$2.2M
30 Jun 2024–-$2.5M
31 Mar 2024–-$6.5M
31 Dec 2023–-$1.9M
30 Sep 2023–-$1.4M
30 Jun 2023–$1.1M
31 Mar 2023–-$2.9M
31 Dec 2022–-$2.9M
30 Sep 2022–-$3.1M
30 Jun 2022–-$3.8M
31 Mar 2022–-$2.9M
31 Dec 2021–-$5.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$120.6M -$8.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $22.0M $4.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$4.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Azora TherapeuticsAZR (this company) $55.0Mloss–––
Boundless BioBOLD $54.8Mloss–––
iBioIBIO $56.4Mloss52.4+115%–
Xilio TherapeuticsXLO $53.4Mloss0.97+73%-20.9%
Impact BioMedicalIBO $53.3M–over 999––
Citius OncologyCTOR $53.2Mloss–––

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

4.9%

700K shares held by 13F filers (30 Sep 2026) of 14.3M outstanding (9 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.5%

217K shares sold short (30 Oct 2026) of 14.3M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.1

217K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+21%

180K shares sold short in the report before, 217K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

4.6%

4.6% of off-exchange volume on 20 Nov 2026 was short sales

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$30K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

12

12 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

12 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $3.85 on 20 Nov 2026, -21% over 12 months (12-month range $3.51 to $4.88)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $106K in the last 12 months (the 12 months before: $0).
Institutional holders (13F filers). 22 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.
Lobbying spend. Lobbying spend: $30K published in the last 12 months, -25% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Nov 20268-K and other filingsAppointed directors Aida Habtezion, Paul Hastings and Thomas Soloway, effective Nov 3, 2026; Soloway named audit committee chair
28 Oct 20268-K and other filingsDirector or officer change
18 Sep 20268-K and other filingsDirector or officer change
21 Aug 20268-K and other filingsDelisting notice or listing transfer
13 Aug 20268-K and other filingsDirector or officer change
18 Jul 2026Lobbying filinglobbying engagement terminated (RK STRATEGIES, INC.)
11 Jun 20268-K and other filingsCompleted an acquisition or asset sale
11 Jun 20268-K and other filingsDirector or officer change
20 Apr 2026Sharp changeLobbying on a new issue: lobbying on a new issue: DEF (2026-03-31)
9 Apr 20268-K and other filingsDirector or officer change
9 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Jan 20268-K and other filingsDirector or officer change
6 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Dec 20258-K and other filingsPrivate placement of securities (Form D)
3 Sep 20258-K and other filingsDelisting notice or listing transfer
1 Aug 20258-K and other filingsA major agreement ended
1 Aug 20258-K and other filingsDirector or officer change
1 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Jun 20258-K and other filingsRegistered new securities for sale (S-1)
6 Jun 20258-K and other filingsRegistered new securities for sale (S-1)
30 May 20258-K and other filingsDelisting notice or listing transfer
13 May 20258-K and other filingsPrivate placement of securities (Form D)
1 May 20258-K and other filingsChanged its auditor
21 Mar 20258-K and other filingsDirector or officer change
21 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Mar 20258-K and other filingsDelisting notice or listing transfer
20 Jan 2025Lobbying filingnew lobbying registration (RK STRATEGIES, INC.)
20 Jan 2025Sharp changeFirst lobbying registration: first lobbying registration: ADIAL PHARMACEUTICALS, INC.: new lobbying registration (RK STRATEGIES, INC.)
20 Dec 20248-K and other filingsRegistered new securities for sale (S-1)
18 Dec 20248-K and other filingsA major agreement ended
6 Dec 20248-K and other filingsDirector or officer change
12 Nov 20248-K and other filingsDirector or officer change
5 Nov 20248-K and other filingsDirector or officer change
5 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Apr 20248-K and other filingsDirector or officer change
16 Apr 20248-K and other filingsDirector or officer change
14 Mar 20248-K and other filingsPrivate placement of securities (Form D)
18 Jan 20248-K and other filingsDirector or officer change
29 Nov 20238-K and other filingsDelisting notice or listing transfer
28 Nov 20238-K and other filingsDelisting notice or listing transfer
8 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
6 Nov 20238-K and other filingsDirector or officer change
26 Oct 20238-K and other filingsPrivate placement of securities (Form D)
21 Sep 20238-K and other filingsDirector or officer change
21 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Aug 20238-K and other filingsDelisting notice or listing transfer
18 Aug 20238-K and other filingsCompleted an acquisition or asset sale
15 Aug 20238-K and other filingsReport will be filed late
13 Jul 20238-K and other filingsRegistered new securities for sale (S-1)
10 Jul 20238-K and other filingsDelisting notice or listing transfer
23 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
2 Jun 20238-K and other filingsPrivate placement of securities (Form D)
24 May 20238-K and other filingsDelisting notice or listing transfer
6 Mar 20238-K and other filingsPrivate placement of securities (Form D)
2 Mar 20238-K and other filingsDelisting notice or listing transfer
13 Oct 20228-K and other filingsDirector or officer change
14 Sep 20228-K and other filingsChanged its auditor
13 Sep 20228-K and other filingsDirector or officer change
2 Sep 20228-K and other filingsDelisting notice or listing transfer
23 Aug 20228-K and other filingsDirector or officer change
23 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 20228-K and other filingsPrivate placement of securities (Form D)
9 Dec 20218-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Dec 2021: $84K published
Month from 1 Jan 2022: $67K published
Month from 1 Oct 2023: $2K published
Month from 1 Jul 2026: $106K published
Institutional holders (13F filers)
30 Sep 2026 report: 22; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2025: $10K published
Quarter from 1 Apr 2025: $10K published
Quarter from 1 Jul 2025: $10K published
Quarter from 1 Oct 2025: $10K published
Quarter from 1 Jan 2026: $10K published
Quarter from 1 Apr 2026: $10K published
Quarter from 1 Jul 2026: $10K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is net income, quarter at -$64.6M (30 Sep 2026), 3055% below its normal quarter of -$2.0M; higher than 3% of its own history.
  • Insider net buying (open market): Insiders bought a net $106K in the last 12 months (the 12 months before: $0).
  • Institutional holders (13F filers): 22 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.
  • Lobbying spend: Lobbying spend: $30K published in the last 12 months, -25% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 21 insider trades

No trades in the last 90 days; the latest was filed 16 Jul 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Jul 2026Coastlands Capital LP10% ownerBuy3,233$2.69$9KForm 4
13 Jul 2026Coastlands Capital LP10% ownerBuy11,753$2.78$33KForm 4
1 Jul 2026Coastlands Capital LP10% ownerBuy25,000$2.60$65KForm 4
3 Oct 2023Kevin SchuylerDirectorBuy700$2.74$2KForm 4
3 Jan 2022James W. Newman Jr.DirectorBuy25,000$2.69$67KForm 4
1 Dec 2021William B. Stilley IIIChief Executive OfficerBuy20,600$2.67$55KForm 4
30 Nov 2021James W. Newman Jr.DirectorBuy10,000$2.85$28KForm 4
6 Oct 2021Bankole A. JohnsonChief Medical OfficerSell200,000Not filedNot filedForm 4

22 institutions reported shares at the end of Q3 2026, 5% of the shares outstanding; 7 opened a position, 2 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
KVP Capital Advisors, LP210K1.47%$843KNew+210K
Diadema Partners LP182K1.27%$729KNew+182K
Acuta Capital Partners, LLC130K0.91%$521KNew+130K
Jane Street Group, LLC54K0.38%$216KNew+54K
Citadel Advisors LLC30K0.21%$119K+206+0.7%
XTX Topco Ltd27K0.19%$107KNew+27K
Geode Capital Management, LLC22K0.15%$86KNew+22K
Vanguard Fiduciary Trust Co16K0.11%$64KNew+16K
China Universal Asset Management Co., Ltd.13K0.09%$53KNew+13K
Vanguard Capital Management LLC10K0.07%$42KNew+10K

In 12 months: 7 director or officer changes, 3 major agreements, 1 private placement, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Nov 2026Appointed directors Aida Habtezion, Paul Hastings and Thomas Soloway, effective Nov 3, 2026; Soloway named audit committee chair8-K
28 Oct 2026Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
18 Sep 2026Director or officer changeSame filing: shareholder vote results8-K
16 Sep 2026Signed a major agreement8-K
21 Aug 2026Delisting notice or listing transfer8-K
13 Aug 2026Director or officer change8-K
11 Jun 2026Director or officer change; Signed a major agreement; Completed an acquisition or asset saleSame filing: took on new debt, sold shares privately, changed its bylaws or fiscal year8-K
9 Apr 2026Director or officer change8-K

Reported lobbying spend: $10K in Q2 2026, $10K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2026EndedRK Strategies, Inc.for Adial Pharmaceuticals, Inc.FDA Issues Related to Addiction H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R. 8800, National Defense Authorization Act for Fiscal Year 2027Health issues, DefenseFiling
20 Dec 2024NewRK Strategies, Inc.for Adial Pharmaceuticals, Inc.Legislation Related To Alcohol Use Disorder Food & Drug Administration PolicyHealth issues, PharmacyFiling

The 5 newest of 42 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 9 Nov 2026Filings record

    Appointed directors Aida Habtezion, Paul Hastings and Thomas Soloway, effective Nov 3, 2026; Soloway named audit committee chair

  2. 28 Oct 2026Filings record

    Director or officer change

  3. 18 Sep 2026Filings record

    Director or officer change

  4. 21 Aug 2026Filings record

    Delisting notice or listing transfer

  5. 13 Aug 2026Filings record

    Director or officer change

  6. 18 Jul 2026Lobbying record

    ADIAL PHARMACEUTICALS, INC.: lobbying engagement terminated (RK STRATEGIES, INC.) (dated 30 Jun 2026)

  7. 17 Jul 2026Insiders record

    Coastlands Capital LP (ten percent owner) bought 3,233 shares of ADIL ($8,691) (dated 16 Jul 2026)

  8. 14 Jul 2026Insiders record

    Coastlands Capital LP (ten percent owner) bought 11,753 shares of ADIL ($32,638) (dated 13 Jul 2026)

  9. 2 Jul 2026Insiders record

    Coastlands Capital LP (ten percent owner) bought 25,000 shares of ADIL ($65,000) (dated 1 Jul 2026)

  10. 11 Jun 2026Filings record

    Director or officer change

  11. 11 Jun 2026Filings record

    Completed an acquisition or asset sale

  12. 20 Apr 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['DEF']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    11156080
  13. 9 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 9 Apr 2026Filings record

    Director or officer change

  15. 6 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 6 Jan 2026Filings record

    Director or officer change

  17. 3 Dec 2025Filings record

    Private placement of securities (Form D)

  18. 3 Sep 2025Filings record

    Delisting notice or listing transfer

  19. 1 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 1 Aug 2025Filings record

    A major agreement ended

  21. 1 Aug 2025Filings record

    Director or officer change

  22. 13 Jun 2025Filings record

    Registered new securities for sale (S-1)

  23. 6 Jun 2025Filings record

    Registered new securities for sale (S-1)

  24. 30 May 2025Filings record

    Delisting notice or listing transfer

  25. 13 May 2025Filings record

    Private placement of securities (Form D)

  26. 1 May 2025Filings record

    Changed its auditor

  27. 21 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 21 Mar 2025Filings record

    Director or officer change

  29. 7 Mar 2025Filings record

    Delisting notice or listing transfer

  30. 20 Jan 2025Lobbying change

    registered for federal lobbying for the first time in our data (Rk Strategies, Inc.).

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  31. 20 Jan 2025Lobbying record

    ADIAL PHARMACEUTICALS, INC.: new lobbying registration (RK STRATEGIES, INC.) (dated 20 Dec 2024)

  32. 20 Dec 2024Filings record

    Registered new securities for sale (S-1)

  33. 18 Dec 2024Filings record

    A major agreement ended

  34. 6 Dec 2024Filings record

    Director or officer change

  35. 12 Nov 2024Filings record

    Director or officer change

  36. 5 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 5 Nov 2024Filings record

    Director or officer change

  38. 26 Apr 2024Filings record

    Director or officer change

  39. 16 Apr 2024Filings record

    Director or officer change

  40. 14 Mar 2024Filings record

    Private placement of securities (Form D)

Showing the newest 40 of 124 entries; narrow the window or the kind of data to see older ones.

Not listed: 160 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001513525
Ticker
AZR
Domain
azoratherapeutics.com
Hq location
CA|ENCINO|91436 (1 unverified)
Lobbying client
adial pharmaceuticals
Name
ADIAL PHARMACEUTICALS, INC., Azora Therapeutics, Inc., Azora Therapeutics, Inc. (DE)
  • Federal lobbying disclosures (LDA)2 records, 21 data points20 Dec 2024 to 30 Jun 2026
  • SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)246 records15 May 2017 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)407 data points31 Dec 2016 to 9 Nov 2026
  • SEC Form 4 insider transactions21 records, 60 data points2 Aug 2018 to 16 Jul 2026
  • FINRA short interest (twice monthly)3 data points30 Oct 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)34 data points29 Oct 2026 to 20 Nov 2026